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Two case-control studies evaluated the prevalence of
community-associated methicillin-resistant Staphylococcus
aureus (CA-MRSA) carriage at hospital admission and
characteristics of patients with CA-MRSA. Among 14,253
patients, CA-MRSA prevalence was 0.9/1,000 admissions.
Although 5 CA-MRSA isolates contained Panton-Valentine
leukocidin, only 1 patient had a previous skin infection. No
easily modifiable risk factor for CA-MRSA was identified. 
R
ecently, new strains of community-associated methi-
cillin-resistant  Staphylococcus aureus (CA-MRSA),
which cause soft tissue infections in healthy people, have
been detected worldwide (1). The unique molecular fea-
ture of these CA-MRSA strains consists of 2 particular
genetic elements, the type IV staphylococcal cassette chro-
mosome (SCC) mec element and a virulence gene encod-
ing a leukocyte-killing toxin called Panton-Valentine
leukocidin (PVL), not found in hospital-acquired MRSA
isolates (1).
Risk factors for CA-MRSA carriage are incompletely
understood. Although antimicrobial drug use is well recog-
nized as risk factor for hospital-acquired MRSA (2),
results of previous investigations have been inconsistent
regarding the association between previous antimicrobial
drug use and acquisition of CA-MRSA (3,4). Recently, 2
studies from North America have suggested that recent
antimicrobial drug use plays a role in CA-MRSAcoloniza-
tion (5,6).
Few systematic studies have assessed the epidemiology
of CA-MRSA in Europe (7). Determining the epidemiolo-
gy of CA-MRSAcould help develop control measures and
guide clinicians in identifying patients at high risk for CA-
MRSA. Therefore, our prospective investigation sought to
1) determine the prevalence of CA-MRSA on hospital
admission, 2) examine characteristics of patients carrying
CA-MRSA, 3) test the hypothesis that previous antimicro-
bial drug exposure is associated with CA-MRSA carriage,
and 4) evaluate the genetic diversity of CA-MRSAstrains.
The Study
Details of this prospective, observational study have
been presented elsewhere (8). In brief, the study popula-
tion consisted of 14,253 patients who were screened for
MRSA carriage on admission to the Geneva University
Hospitals between January 20, 2003, and August 31, 2003.
Of these patients, 12,072 (85%) were hospitalized in the
adult wards, 102 (1%) in pediatric wards, and 361 (2%) in
psychiatric wards; 1,718 (12%) were seen in the emer-
gency room and were discharged within 24 hours. MRSA
screening was performed by nasal and inguinal swab sam-
ples, and cultures of specimens from other sites were per-
formed when clinically indicated. A person fulfilled the
CA-MRSA case definition if 1) the person had an MRSA
isolate that yielded a SCCmec type different from the pre-
vailing hospital-associated strain in the Geneva region
(SCCmec type I [9]) and 2) the person had not been hospi-
talized within the last 3 years (3).
We performed 2 case-control studies. The first control
group comprised all patients with MRSA carriage identi-
fied on admission who did not fulfill our case-definition of
CA-MRSA. If a patient was admitted more than once dur-
ing the study period, only the first admission was included
in this analysis. The second control group consisted of a
group of randomly selected MRSA-negative patients. The
following potential risk factors for CA-MRSA carriage
were documented: age, sex, origin of patient, coexisting
conditions, severity of underlying illness, functional status,
patient’s prior location, presence of skin lesions, and
antimicrobial drug use within the past 6 months.
MRSA was identified according to NCCLS guidelines
(10). Typing of SCCmec elements and detection of PVL
genes were carried out as described (9). A novel multiplex
polymerase chain reaction (PCR) based assay was used for
rapid genotyping of S. aureus isolates (11). This assay is
based on variable-number tandem repeat typing (12) and
has been modified to allow high throughput and automat-
ed analysis. In addition, 13 CA-MRSAisolates, 2 hospital-
acquired MRSA isolates, and 2 references strains from the
United States were genotyped by multilocus sequence typ-
ing (MLST) (13). PCR products were sequenced with an
ABI Prism 3100 DNA sequencer (Applied Biosystems,
Foster City, CA, USA). Allele numbers were assigned
according to the program available from the MLST Web
site (http://www.mlst.net).
We used the Student t test to compare continuous
variables and the chi-square test or Fisher exact test to
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*University of Geneva Hospitals, Geneva, Switzerland compare proportions. Univariate comparisons were per-
formed to determine characteristics of CA-MRSApatients.
Data were analyzed with STATA, version 8.0 (Stata Corp,
College Station, TX, USA).
During January through August 2003, 428 of 14,253
screened patients were discovered to be MRSAcarriers on
admission (prevalence 3.0%). Most MRSA isolates
belonged to the type I cassette (n = 371, 26/1,000 admis-
sions). MRSA SCCmec type IV was recovered in 46
patients (3.2/1,000 admissions), whereas types II, III and V
were only rarely identified (n = 11). Thirty-seven of 46
patients (80%) with SCCmec type IV isolates had previous
contact with the healthcare system, in particular with hos-
pitals in neighboring France.
Thirteen patients fulfilled our case definition for having
CA-MRSA (prevalence 0.9/1,000 admissions). The preva-
lence of CA-MRSAvaried according to the hospital sector:
it was highest in pediatric patients (9.8/1,000), followed by
adult outpatients staying <24 hours (1.7/1,000) and adult
inpatients (0.7/1,000). Important features of the 13 CA-
MRSA cases are shown in the Table. Six CA-MRSA
patients lived outside Switzerland: Kosovo (n = 2), France
(n = 1), Senegal (n = 1), Madagascar (n = 1), and Libya (n
= 1).
Ten CA-MRSA isolates harbored the SCCmec type IV,
2 the type V, and 1 the type II element (Figure). All CA-
MRSA isolates were susceptible to trimethoprim-sul-
famethoxazole, clindamycin, and vancomycin. Two
isolates (SCCmec type V) were resistant to gentamicin; 2
other isolates (SCCmec type IV) showed resistance to flu-
oroquinolones; and 1 (SCCmec type II) was resistant to
macrolides. Although 5 (38%) of 13 CA-MRSA isolates
possessed the pvl gene, only 1 patient had a skin infection
on admission. The other 4 patients had no history of
infection.
Genetic analysis combining genotyping and MLST
showed substantial diversity among CA-MRSA isolates
(Figure). In particular, they were not related to the nosoco-
mial strain endemic in the Geneva hospital setting (strains
B5-63 and B5-64). Dendrogram analysis identified 2
closely related CA-MRSA isolates from patients living in
Geneva (strains B2-55 and B3-11) who had never been
hospitalized and had no apparent epidemiologic link. The
pattern of 1 CA-MRSAisolate (B2-19), from a 38-year-old
Geneva woman who used injection drugs, was related to
the MW2 strain from North Dakota.
MLST of CA-MRSA isolates identified 7 sequence
types (ST-1, -5, -8, -45, -80, -88, and -152), belonging to
patients from different geographic origins (Figure). Five
strains represented 2 distinct ST clones (ST-45 and ST-
152) previously described in northern Europe and Israel; 1
isolate was related to the prototype CA-MRSA strain
MW2 (ST-1); and 2 isolates corresponded to a clone
reported from Asia (ST-88). The largest cluster contained
strains previously described from several continents,
including French clone ST-8, Mediterranean clone ST-80,
and the international, so-called pediatric clone ST-5
(SCCmec type IV).
Patients with CA-MRSA differed in several ways from
those who carried healthcare-associated MRSA (n = 346)
and those who were free of MRSA on admission (n =
1,542, Table). Patients with CA-MRSA were younger and
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Switzerland. Compared to non-MRSA controls, no signif-
icant differences were noted in previous outpatient antimi-
crobial drug use and presence of coexisting conditions
(Table). By contrast, CA-MRSA patients had fewer coex-
isting conditions and less prior exposure to antimicrobial
drugs than patients with healthcare-associated MRSA. The
presence of skin lesions on admission was not predictive of
CA-MRSA carriage.
Conclusions
This study provides information about the epidemiolo-
gy of CA-MRSA on admission to the largest hospital in
Switzerland. It showed 1) a low prevalence of CA-MRSA,
2) a reservoir of asymptomatic persons colonized with
PVL-containing CA-MRSA strains, 3) a high degree of
CA-MRSAdiversity, and 4) no readily modifiable risk fac-
tor for CA-MRSA carriage.
Several investigators have recently attempted to
describe the epidemiology of CA-MRSA more precisely
(5,14). These study findings are not consistent since they
were conducted in different settings and used various case
definitions (3). Typically, most studies used an epidemio-
logic case definition that excluded patients with recent
healthcare system contact in whom MRSA was detected
within 48 hours after hospital admission (15). This type of
study, however, cannot prove that MRSA acquisition was
unrelated to healthcare system contact. Therefore, how to
define true community-acquired MRSA remains contro-
versial. Although we added a molecular component to
increase the validity of our case definition, we used the
more conservative term “community-associated” MRSA,
since we cannot exclude the fact that CA-MRSA case-
patients may have previously been in contact with outpa-
tient care or hospitalized family members.
Described risk factors associated with CA-MRSA
infection include intravenous drug use, military training,
jail exposure, team sport activities, homosexuality, low
socioeconomic class, and being member of a “closed pop-
ulation” such as Native Americans and Australian aborig-
ines (5,6). Two recent analyses found an increased risk in
patients exposed to antimicrobial drugs (5,6). Our study
did not confirm this hypothesis, making it unlikely that
antimicrobial drug control measures will substantially
decrease transmission of CA-MRSA.
Control of CA-MRSAremains a challenge, since trans-
mission is linked to migration and travel (16). Our study
showed that the ratio of 4:1 between colonization and
infection with CA-MRSA possessing the pvl gene was
larger than previously thought. Restricting surveillance to
infected carriers will underestimate the prevalence of
PVL-producing CA-MRSA. Thus, CA-MRSA surveil-
lance should not rely on clinical specimens alone.
Several study limitations merit consideration. First, we
may have underestimated CA-MRSAprevalence since our
study was not truly population-based. Second, we may
have misclassified CA-MRSA cases. Thorough review of
medical charts minimized this potential bias. Finally, we
were not able to elucidate the route of transmission for
those CA-MRSAcarriers living in the Geneva community.
MLST results suggest that nonendemic hospital strains
may already circulate in the Geneva community.
In summary, the prevalence of CA-MRSA remains rel-
atively low in our community. Yet migration will likely
increase CA-MRSAcarriage in the near future. This devel-
opment will influence clinical practice by changing the
choice of empiric antimicrobial drug therapy for severe
skin and soft tissue infections.
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